Conference Day One - Wednesday, May 15, 2024
7:45 am Check-In & Coffee
8:45 am Chair’s Welcoming Remarks
Unveiling the Potential of GLP-1s: Exploring Applications Beyond Diabetes & Obesity
9:00 am Unlocking Cardiovascular Potential: Presenting the Latest Evidence Supporting Positive Outcomes with GLP-1s
Synopsis
- Exploring evidence supporting positive cardiovascular outcomes of GLP-1s to reveal the possibility of a cardiovascular market for therapies
- Considering approaches, including the use of agonist combinations, to gain positive cardiovascular outcomes
- Navigating potential challenges that may arise in the context of employing GLP-1 treatments for cardiovascular indications
9:30 am Can GLP-1 Agonists Represent a Meaningful Therapeutic Option for People with Obstructive Sleep Apnea (OSA)?
Synopsis
- Discussing the clinical and economic burden of OSA
- Understanding the basic pathophysiology of the disease and why GLP-1 RAs may be a valid treatment option
- Evaluating the current treatment options for OSA and exploring the benefits GLP-1 RAs may bring
- Reflecting on challenges and future plans to expand GLP-1 therapies into this area
10:00 am Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease
Synopsis
- Navigating the rationale behind using GLP-1s to treat MASH and fatty liver disease
- Understanding the limitations of GLP-1 monotherapy and GLP-1/GIP dual agonists and the therapeutic benefit of glucagon-based agents
10:30 am Speed Networking
Synopsis
This valuable session will be time for structured networking, where you can connect with peers and forge exciting new connections
11:00 am Morning Break & Refreshments
11:30 am Advancing DD01, a Ratio Optimized GLP-1/GCG Agonist for Rapid Liver Fat Reduction Regardless of Body Weight Loss & Exploring Novel Approaches for Oral Peptide Delivery
Synopsis
- Focusing on phase 1 clinical data of GLP-1/GCG treatment in obese/overweight patients with T2D and/or NASH
- Understanding the significance of rapid liver fat reduction in NAFLD/NASH patients with GLP-1/GCG dual agonists
- Introducing novel methods to orally deliver peptide drugs, improving ease of administration
12:00 pm How Can Imaging Support the Understanding of Drug Development of GLP-1’s?
Synopsis
Full session details to be announced
12:30 pm Lunch Break & Networking
1:30 pm Exploring Current Evidence to Support the Expansion of GLP-1s into Renal Indications
Synopsis
- Exploring the reasons behind the potential benefits of GLP-1s in this therapeutic domain, and assessing the necessity of creating novel treatments for renal diseases
- Examining the supporting evidence for GLP-1s in renal indications to conclude their effectiveness in this patient population
- Deliberating on challenges and future strategies to extend the application of GLP-1 therapies into this specific area
2:00 pm Uncovering the Hidden Benefits of GLP-1s Using Quantitative MRI: From Obesity to Obstructive Sleep Apnea & Everything In Between
Synopsis
- GLP-1s elicit significant weight loss, but where? Exploring the use of quantitative MRI for studying body composition changes in GLP-1 trials.
- Highlighting the role of quantitative multi-organ MRI for enriching clinical trials and demonstrating the multi-organ benefits of GLP-1 treatments.
- Digital strategy and combining quantitative MRI with traditional biomarkers for deep participant phenotyping
2:30 pm Roundtable Discussion: Discussing the Future Indications of GLP-1-Based Therapeutics – Promises & Challenges
Synopsis
- Advancing the reach of GLP-1-based treatments into other therapeutic areas, particularly Alzheimer’s and Parkinson’s disease
- Exploring the scientific validity of the latest treatment frontiers with GLP-1s to understand the potential in these areas
- Considering the commercial possibilities of these new therapeutic area markets to grasp the scope of opportunity
3:00 pm Panel Discussion: Exploring the Therapeutic Potential of GLP-1s – Assessing New Indicative Benefits & Their Association with Weight Loss
Synopsis
- Evaluating the impact of GLP-1s: are all observed benefits attributable to weight reduction or are other mechanisms in play?
- Considering how co-morbidities should be addressed from a clinical and commercial strategy perspective
- Clarifying uncertainties related to expanding into numerous new therapeutic areas
3:45 pm Afternoon Break & Networking
Optimizing Efficacy of GLP-1-Based Therapeutics for Weight Loss Treatment to Assess Efficacy as a Benchmark of a Successful Treatment
4:15 pm Oral Delivery of GLP-1 and other Incretins: Targeting both Hepatic and Peripheral Uptake to Improve Patient Outcomes
Synopsis
- Hepatic targeting of incretins in metabolic diseases – the importance of mimicking normal physiology
- Highlighting a novel oral delivery platform, hepatic directed vesicles (HDV)
- Reviewing the potential benefits of dual targeting for GLP-1 in both hepatic and peripheral uptake
4:45 pm Beyond BMI: Using AI-Based Phenotyping to Understand GLP-1 Treatment Outcomes Across the Patient Journey
Synopsis
- Identifying positive and negative impacts of GLP-1 treatment across organ systems using real-world data
- Using AI-based digital phenotyping to isolate distinct patient profiles based on likely outcomes, before and during treatment
- Assessing the balance among different treatment effects for personalized decision-making
5:15 pm Investigating Combination Therapy with an Oral Apelin Receptor Agonist to Increase the Efficacy of Incretin Drugs for Weight Loss
Synopsis
- Focusing on strategies for combining oral GLP-1s with complementary mechanisms to achieve injectable-like weight loss with improved body composition
- Reviewing pre-clinical data showing that azelaprag, a first-in-class apelin receptor agonist that improved muscle metabolism in older people in a Ph1b study, fully restores body weight, body composition, and muscle function to that of lean controls
- Highlighting the potential of azelaprag to increase weight loss and improve body composition in older obese patients in a Ph2 trial of azelaprag + tirzepatide coadministration